CODEN [USA]: IAJPBB ISSN : 2349-7750

INDO AMERICAN JOURNAL OF
PHARMACEUTICAL SCIENCES

SJIF Impact Factor: 7.187

https://doi.org/10.5281/zenodo.17763593

Available online at: http://www.iajps.com Review Article

A PROSPECTIVE OVERLOOK ON SICKLE CELL DISEASE PREVENTION, DIAGNOSIS AND TREATMENT

[1]Harish Ramesh Bhudolkar,[2] Ashwini Dipak Uke

[1]Student, Vardhaman College Of Pharmacy, Koli, Karanja (Lad) Washim

[2]Assistant professor :- M pharm in Pharmaceutical Chemistry, Vardhaman College Of Pharmacy, Koli, Karanja(Lad), Maharashtra, India.

Abstract:

Sickle cell anemia (SCA) remains a major global health concern owing to its significant morbidity and mortality rates worldwide [1]. Recent progress in diagnostic technologies and therapeutic methods has substantially advanced the management of this hereditary hemoglobin disorder. This review summarizes current developments in SCA diagnostics, including genetic testing, hemoglobin electrophoresis, and advanced imaging modalities, emphasizing their precision and clinical relevance [2,3]. Emerging therapeutic strategies such as gene-editing approaches, fetal hemoglobin induction, and targeted molecular treatments are also examined for their ability to reduce complications and enhance patient outcomes [4–6]. Additionally, the paper highlights the importance of integrated care models and discusses future directions in early detection, personalized therapy, and ongoing research efforts [7]. A thorough understanding of these advancements is essential for improving clinical management and prognosis for individuals affected by sickle cell anemia.

***Keywords**: sickle cell anemia, anemia, treatment, diagnosis*

Corresponding author:

Harish Ramesh Bhudolkar,

Student,

Vardhaman College Of Pharmacy,

Koli, Karanja (Lad) Washim

QR CODE

Please cite this article in press Harish Ramesh Bhudolkar et al., A Prospective Overlook On Sickle Cell Disease Prevention, Diagnosis And Treatment, Indo Am. J. P. Sci, 2025; 12(11).

INTRODUCTION:

The coexistence of diabetes mellitus and sickle cell anemia presents a uniquely challenging clinical scenario, merging two complex disorders that each demand careful, continuous management. Diabetes involves chronic disturbances in glucose regulation, whereas sickle cell anemia is an inherited hemoglobinopathy characterized by the production of abnormal hemoglobin that drives red blood cell deformation, vaso-occlusive episodes, and progressive organ injury. When these two conditions overlap, they create a distinct clinical spectrum often referred to as sickle cell trait-related diabetes (SCTD), which introduces additional diagnostic and therapeutic difficulties.

Globally, diabetes continues to rise at an alarming rate and significantly strains healthcare systems due to its numerous systemic complications. At the same time, sickle cell anemia remains a major public health concern, especially in regions with historically high malaria prevalence. Understanding the separate epidemiology of these diseases is essential for appreciating the broader impact of their coexistence. Notably, individuals with sickle cell trait (SCT) have been shown to carry an elevated risk of certain comorbidities such as hypertension and kidney disease. Emerging research also suggests that SCT may predispose individuals to diabetes, prompting renewed interest in the underlying biological connections. The interaction between hemoglobin S and abnormal glucose metabolism creates a complex xpathophysiological environment. The presence of sickle hemoglobin alters red blood cell flexibility, tissue oxygenation, and vascular reactivity—factors that may intersect with mechanisms that regulate insulin sensitivity and glucose control. These relationships highlight the need for an in-depth exploration of the molecular and cellular processes that drive SCTD.

Diagnosing diabetes in individuals with sickle cell anemia is particularly challenging. Variations in hemoglobin structure and lifespan can interfere with the accuracy of standard diagnostic tools such as HbA1c, making glycemic monitoring more complicated. This necessitates the use of tailored diagnostic and monitoring strategies that account for the altered physiology seen in SCTD.

The diversity among patients with SCTD underscores the importance of individualized care. Advances in genetic profiling offer opportunities to predict risks, anticipate complications, and design patient-specific treatment plans. Such precision-based approaches hold promise for improving outcomes in individuals who live with both diabetes and sickle cell anemia.

Each condition independently increases the risk of complications involving the cardiovascular system, kidneys, and eyes. When they occur together, these risks may be amplified, making it critical to Hydroxyurea possesses many features that make it a valuable therapeutic option for individuals with sickle cell anemia (SCA), offering benefits through several complementary biological actions. Over the past few decades, extensive clinical experience has confirmed both its safety and effectiveness. Initial proof-of-concept investigations were followed by phase 1 and 2 clinical trials in adults, and later in adolescents, children, and even infants. The pivotal phase 3 multicenter trial funded by the National Heart, Lung, and Blood Institute clearly demonstrated that hydroxyurea significantly reduces acute vaso-occlusive episodes in adults with severe disease. With this growing body of evidence, hydroxyurea is now recognized as an important treatment for children and adolescents experiencing recurrent painful crises, with more recent data showing long-term protection and even reversal of certain chronic complications.

Despite its proven benefits, hydroxyurea remains underutilized in real-world clinical practice. Many healthcare providers are insufficiently familiar with the drug, leading to missed opportunities to offer it to eligible patients. Families may also be hesitant due to misconceptions or exaggerated concerns regarding side effects. In addition, inconsistent healthcare infrastructure and limited advocacy support contribute to its low uptake. Although some questions remain about its long-term effects, current evidence indicates that many young patients with SCA could greatly benefit from hydroxyurea therapy



Fig . No. 1 sickle cell anemia

REVIEW OF LITERATURE

1. **World Health Organization**. WHO recommendations on the management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period. Geneva: WHO; 19 June 2025. World Health Organization

2. **U.S. Food and Drug Administration.** FDA approves first gene therapies to treat patients with sickle-cell disease (CASGEVY and others). 8 Dec 2023.
U.S. Food and Drug Administration

3. **Pfizer. Pfizer voluntarily withdraws all lots of OXBRYTA (voxelotor) for SCD.** 25 Sept 2024.

4. **Quarmyne MO. Newborn Screening for Sickle Cell Disease and Thalassemia.** JAMA Health Forum. 2025. (Discusses adoption of molecular NBS).

5. **Vertex & CRISPR Therapeutics. Press release:** FDA approval of CASGEVY (exagamglogene autotemcel). 8 Dec 2023.

6. Aygün B., et al. Hydroxyurea dose optimisation and REACH program outcomes for children with SCD. Lancet Haematology, 2024.

7. **FDA.** Casgevy (exagamglogene autotemcel) product page and approval materials. Feb 2024.
U.S. Food and Drug Administration

8. **FDA Drug Safety Communication**. Alerting patients/health professionals about Oxbryta withdrawal. 26 Sept 2024. U.S. Food and Drug Administration

9. **ASH Clinical News**. Coverage of voxelotor withdrawal and implications. 2024–2025.

Ash Publications

10. **Reuters.** Reporting on Pfizer withdrawal of Oxbryta and safety concerns. 25 Sept 2024

RESEARCH GAPS

1. Gaps in Prevention

Limited Newborn Screening Programs

Although newborn screening is effective, many low- and middle-income countries still lack universal screening programs. Studies highlight inadequate coverage but do not fully explore cost-effective models for universal screening in resource-poor settings.

Insufficient Awareness and Genetic Counseling

There is a major gap in evaluating the impact of community-based genetic education, especially in rural populations. Few studies assess long-term outcomes of premarital or antenatal counseling programs.

Lack of Preventive Policy Implementation Research

Existing literature focuses on prevention strategies but rarely analyzes policy barriers, funding challenges, and feasibility of integrating SCD testing into national health systems.

2. Gaps in Diagnosis

Limited Use of Point-of-Care Diagnostics

While several rapid tests are validated, there is limited research on scalability, accuracy in field conditions, and their integration into routine primary care.

Genotype–Phenotype Correlation Unclear

There is insufficient evidence linking specific genetic markers to disease severity. More studies are needed on molecular modifiers (e.g., HbF levels, α-thalassemia) in diverse populations such as India.

Lack of Early Screening in High-Risk Adults

Most programs focus on newborns; minimal research exists on adult carrier detection, especially in underserved tribal communities.

3. Gaps in Treatment

Under-utilization of Hydroxyurea

Even though hydroxyurea is effective, its real-world usage remains low. There is a gap in understanding: long-term safety in specific populations,
barriers to its acceptance,dosage optimization for children vs adults.

Limited Access to Advanced Therapies

Biologic agents like crizanlizumab and voxelotor show promise, but evidence is limited about: effectiveness in non-Western populations, cost-effectiveness in low-resource settings, long-term side effects.

Stem Cell Transplantation Not Widely Applicable

HSCT is curative, but very few studies address: donor scarcity tsolutions, reduced-toxicity conditioning regimens, psychosocial outcomes post-transplant.

MECHANISM OF ACTION OF HYDROXYUREA

Although hydroxyurea's positive laboratory and clinical effects in SCA are well-documented, the precise molecular pathways through which it increases fetal hemoglobin (HbF) are not fully clarified. Research suggests that several mechanisms work together to produce both HbF elevation and a range of additional therapeutic benefits.

A central mechanism involves the inhibition of ribonucleotide reductase (RR), an enzyme responsible for producing deoxynucleotides required for DNA synthesis. Hydroxyurea blocks the M2 subunit of RR, reducing the supply of deoxynucleotide triphosphates and slowing DNA replication, particularly during the S phase of the cell cycle. Because hydroxyurea is rapidly absorbed and cleared, its effect on RR is temporary, but daily dosing leads to intermittent suppression of erythroid precursors. This controlled cellular stress alters erythropoiesis and favors the production of red blood cells with increased HbF.

Hydroxyurea's therapeutic impact extends far beyond HbF induction. By reducing bone marrow production of neutrophils, reticulocytes, and platelets cells that contribute to inflammation and vaso-occlusion it decreases several key drivers of SCA-related complications. Elevated white blood cell counts have been linked to worse outcomes in SCA, so lowering them can be beneficial by itself. Both neutrophils and reticulocytes express adhesion molecules that promote vascular blockage; hydroxyurea reduces their numbers and diminishes their adhesive properties.

The drug also improves the quality of circulating red blood cells. As dosing increases toward a patient's maximum tolerated dose (MTD), red cells become larger (macrocytosis), better hydrated, less prone to hemolysis, and less likely to form sickled shapes. These changes result in improved blood flow, higher hemoglobin levels, and reduced markers of hemolysis such as LDH and bilirubin. Concerns about increased viscosity due to higher hemoglobin concentrations have not been supported clinically, likely because the overall improvements in cell deformability and reduced adhesion offset any potential thickening of the blood.

Another important feature of hydroxyurea is its ability to release nitric oxide (NO), possibly through still-uncertain metabolic pathways. NO promotes vasodilation and enhances endothelial function, potentially counteracting the NO depletion associated with chronic hemolysis in SCA.

COMPLICATIONS

In sickle cell disease, acute complications can include ischemic events, vaso-occlusive pain crises, acute chest syndrome, stroke, splenic sequestration, acute kidney injury, and



Fig.No.2 Complications Of sickle cell Anemia

gallbladder inflammation Long-term complications may involve persistent pain, gallstone formation, progressive kidney impairment, systemic or pulmonary hypertension, eye damage due to retinopathy, chronic leg ulcers, and avascular necrosis affecting the femoral or humeral heads.Individuals with SCD are also more vulnerable to serious infections andsepsis [58].

LABORATORY DIAGNOSIS

A. Conventional Diagnostic Methods

1. Screening Tests

Sickling and Solubility Tests:

Sickling-based screening relies on the fact that hemoglobin S (HbS) polymerizes when oxygen levels are low. The solubility test is the method used most commonly today. In this assay, a concentrated phosphate buffer, a hemolytic agent, and sodium dithionite are added to the blood specimen. These reagents promote the crystallization of HbS, making it insoluble. The precipitated hemoglobin causes the solution to appear cloudy, and the result is interpreted by comparing it with positive and negative controls.

Paper-Based Solubility Method:

Another screening technique uses chromatography paper. A drop of blood is mixed with a solubility reagent (1:10 ratio), placed on the paper, and stained. The pattern of the stain varies depending on the type of hemoglobin present, enabling identification of HbSS, HbAS, or HbAA individuals. Reported sensitivity is about 94.2%, with specificity around 97.7% for visual detection of HbS. In individuals with HbSS, the test typically shows a reddish deposit and a clear filtrate.

2. Full Blood Count (FBC)

The FBC is often the first investigation used when evaluating anemia. Because sickle cell disease alters hemoglobin structure, affected patients usually show changes in routine hematological indices. Common findings include:

- Anemia
- Increased neutrophil count
- Elevated platelet count
- High mean corpuscular volume (MCV)
- Raised red cell distribution width (RDW)

3. Peripheral Blood Film (PBF)

A peripheral blood smear is performed when automated cell counts show abnormalities. It remains a key step in hematologic assessment because it allows direct visualization of red and white blood cell morphology. With increasing complexity in identifying subtle abnormalities, computerized systems have been introduced to aid interpretation. In sickle cell anemia, typical smear characteristics include:

- Normocytic, normochromic red cells
- Irreversibly sickled cells
- Nucleated red cells
- Target cells
- Neutrophilia
- Thrombocytosis

4. Hemoglobin Electrophoresis

Electrophoresis, a form of chromatographic separation, is an essential method for identifying hemoglobin variants. Charged hemoglobin molecules migrate differently in an electric field depending on pH and the medium. Cellulose acetate (alkaline pH) and citrate agar (acid pH) are commonly used. This method was historically used to characterize HbS as early as 1949.

B. Advanced Diagnostic Methods

1. Prenatal Diagnostic Testing Amniocentesis:

Amniocentesis is performed mainly between 15–20 weeks of pregnancy to detect genetic or chromosomal disorders such as sickle cell disease, thalassemia, or Down syndrome. Under ultrasound guidance, a fine needle is inserted through the abdomen to withdraw amniotic fluid, which contains fetal cells. The entire procedure lasts around 10 minutes, though the clinic visit may take about half an hour. Analysis of fetal DNA reveals whether the fetus carries sickle cell mutations.

Chorionic Villus Sampling (CVS):

CVS can be carried out earlier, usually from 10–14 weeks of pregnancy. A small piece of chorionic villi—tissue that shares the same genetic makeup as the fetus—is collected either through the abdominal wall or via the cervix. Ultrasound guidance ensures accuracy. The sample is examined immediately to confirm adequacy, and fetal DNA is then analyzed for hemoglobin gene mutations. CVS offers earlier diagnosis but may carry a small risk of miscarriage depending on the sampling route.

2. High-Performance Liquid Chromatography (HPLC)

HPLC separates hemoglobin fractions according to their interaction with the stationary phase. Each hemoglobin variant elutes at a characteristic retention time, producing a distinct peak. The system can quantify HbF, HbA2, HbS, HbC, HbBarts, and several other variants. HPLC is more sensitive than electrophoresis and is highly suitable for routine monitoring, especially in patients receiving transfusions or hydroxyurea therapy. Despite its advantages, HPLC is costly and cannot differentiate variants that share similar retention times, which may lead to misidentification. For this reason, it should be paired with confirmatory methods such as DNA analysis.

3. Genetic Analysis

Genetic testing precisely identifies mutations in the

β-globin gene associated with sickle cell disease.

A). PCR-Based Techniques:

PCR uses specific primers and thermostable enzymes to amplify DNA sequences, allowing detection of single-gene mutations in a short time. Variants can be identified through gel electrophoresis, sequencing, fluorescence, or melting curve analysis. High-resolution melting (HRM) is a sensitive, low-cost option for large-scale screening. Other methods, such as bidirectional allele-specific amplification, enable accurate genotyping of homozygous and heterozygous states by producing different band patterns on agarose gels.

b. Restriction Fragment Length Polymorphism (RFLP):

RFLP identifies mutations based on the action of restriction enzymes. The classic example in sickle cell diagnosis is the loss of the MstII recognition site caused by the HbS mutation. In individuals with normal βAβA, the enzyme cuts the DNA, producing two bands. In heterozygous carriers (βAβS), the βA allele is cut while the βS allele is not, resulting in three bands. In homozygous sickle cell patients (βSβS), the mutation prevents enzyme cutting, producing a single large band. Another enzyme, DdeI, is also used, as the sickle mutation removes its recognition site and leads to distinct fragment patterns.

4. Lateral Flow Immunoassay

Lateral flow assays provide rapid, point-of-care detection. One example is the Sickle SCAN test, which uses polyclonal antibodies specific for HbA, HbS, and HbC. Blood applied to the strip migrates through an absorbent pad; hemoglobin binds to antibody-linked nanoparticles and forms visible lines on the test strip. Four lines may appear: a control line plus separate detection lines for HbA, HbS, and HbC. Results are available within minutes and the test costs only a few dollars. Validation studies using venous, dried, and spiked samples have demonstrated high sensitivity and specificity for HbSS, 98.4% and 98.6%, respectively, and 100% accuracy for HbSC disease. The test remains reliable even in newborns with high HbF levels. Limitations include the possibility of visual misinterpretation, cross-reactivity, and occasional false positives in HbAS individuals. Additional field validation has been recommended for primary healthcare settings.

MANAGEMENT AND TREATMENT

1. Pain Management

- Acute vaso-occlusive crisis

Management begins with aggressive hydration and adequate analgesia. Patients are typically admitted for intravenous fluids, such as normal saline or 5% dextrose in saline, to correct dehydration and compensate for ongoing fluid losses from fever or insensible losses. Hydration must be sufficient to restore fluid balance and prevent further sickling.

- **Chronic pain management**

Long-acting oral opioids, such as sustained-release morphine, along with acetaminophen and NSAIDs, are commonly used. NSAIDs, in particular, are effective for deep musculoskeletal pain. Patients may also require short-acting opioids for breakthrough pain; weaker agents like codeine or hydrocodone are used initially, with stronger opioids reserved for more severe pain. Tricyclic antidepressants may enhance pain control by modulating pain perception and improving coexisting depression, which often exacerbates chronic pain.

- **Non-pharmacologic approaches**

Complementary methods can significantly improve comfort. These include physical therapy, application of heat or cold, acupuncture and acupressure, hypnosis, and transcutaneous electrical nerve stimulation (TENS). Studies have shown that these techniques can substantially reduce pain.

2. Blood Transfusions

Red blood cell transfusions are used both therapeutically and preventively in sickle cell disease. By increasing the number of healthy red blood cells, transfusions help decrease complications such as stroke and severe anemia. Children with abnormal transcranial Doppler (TCD) ultrasound findings often receive regular transfusions to reduce their first-stroke risk. Transfusions are also used when hydroxyurea is ineffective or not tolerated.

However, transfusions carry risks, including alloimmunization, infections, and iron overload. Persistent iron accumulation can damage major organs such as the heart and liver, requiring iron-removal therapy.

3. Drug Therapy

Hydroxyurea received FDA approval for adults in 1998 and was later approved for children under two years old in 2017 due to its ability to reduce pain crises and transfusion needs. More recently, three additional medications—L-glutamine, crizanlizumab, and voxelotor— have expanded treatment options by addressing different mechanisms of the disease. Other emerging therapies aim to increase fetal hemoglobin levels, reduce sickling or cell adhesion, or alter red blood cell metabolism.

- **L-glutamine**

This amino acid supports the production of cellular antioxidants such as glutathione and NAD. By reducing oxidative stress on red blood cells, it helps lower the frequency of pain episodes, although its exact mechanism in sickle cell disease is not fully understood. Common side effects include gastrointestinal discomfort and headaches

- **Crizanlizumab**

Inflammation-induced expression of P-selectin promotes the binding of neutrophils, platelets, and sickled cells to the vessel wall, leading to vaso-occlusion. Crizanlizumab is a monoclonal antibody that inhibits P-selectin, thereby reducing these interactions. Given monthly by intravenous infusion, it decreases pain crises in adults and adolescents aged 16 and older. Reported adverse effects include headaches, back pain, nausea, joint pain, and limb pain

.• Voxelotor

Sickling begins with polymerization of deoxygenated HbS. Voxelotor is an allosteric modulator of hemoglobin that increases its affinity for oxygen, reducing polymerization and hemolysis. It is administered orally to adults and children aged 12 and older. Benefits include improved anemia and better blood flow. Potential side effects include headaches, gastrointestinal symptoms, joint pain, fatigue, and skin rash.

4. Stem Cell Transplant

Stem cell or bone marrow transplantation remains the only established cure for sickle cell anemia, but it is limited by the need for a suitable donor and the patient's age and overall health. The procedure typically relies on an HLA-matched sibling donor. Although curative, it carries significant risks such as severe infections, seizures, organ damage, and graft-versus- host disease. Mortality rates are low but present, with about 5% of patients experiencing fatal complications.

5. Gene Therapy

Gene therapy aims to correct or compensate for the defective hemoglobin gene. Thiscollecting the patient's own stem cells, modifying them in the laboratory, and reinfusing them. Approaches include repairing the sickle mutation itself or activating alternative hemoglobin production (such as fetal hemoglobin) to prevent sickling. This treatment offers a potential cure even for patients without a suitable donor.

MANAGEMENT OF STEADY STATE

- Folic acid supplementation
- Prevention of infection improves chances of survival in SCA
- Penicillin prophylaxis, commencing in infancy and continued until age 5 years
- The use of a pneumococcal vaccine at age 2 years with a booster dose at age 5 years greatly reduces the frequency of infections with S pneumoniae
- In the adult patient, all infections must be treated promptly with broad-spectrum antibiotics until a causative organism is identified and therapy is tailored according to its antibiotic sensitivity

MANAGEMENT OF COMPLICATIONS

Generally involves; specialist care and co management Special tests; TCD, ECHO, serum ferritin and iron monitoring Exchange blood transfusion Use of hydroxyurea Use of erythropoietin Dialysis PREVENTION

- Early diagnosis and treatment; prevents complications
- Prompt treatment of acute presentations; prevents complications
- Rehabilitation of those who have developed life changing events
- Premarital screening, targeted at secondary school students
- Prenatal diagnosis

Fig. No. 3 prevention of sickle cell anemia

FUTURE PERSPECTIVES

Gene editing has emerged as a promising therapeutic direction for sickle cell anemia, with researchers aiming to boost fetal hemoglobin (HbF) levels. This strategy is being explored in parallel with hematopoietic stem cell transplantation (HSCT), and several gene-editing methods are currently progressing through clinical trials.One approach uses lentiviral vectors to introduce modified beta- or gamma-globin genes into a patient's cells. The goal is to decrease the proportion of sickle hemoglobin (HbS) while increasing either normal adult hemoglobin (HbA) or fetal hemoglobin (HbF). Another major technique involves CRISPR gene editing, which focuses on suppressing the BCL11A gene an important regulator that normally limits gamma-globin production. By editing the erythroid-specific enhancer region of BCL11A on chromosome 2, its activity is reduced. This allows for greater gamma-globin expression and ultimately leads to higher HbF levels, which can help counteract the effects of HbS.

CONCLUSION:

Understanding the latest progress in diagnosing and treating sickle cell anemia plays an essential role in improving the quality of life for individuals affected by this inherited blood disorder. Staying informed empowers patients, their families, and healthcare providers to make thoughtful decisions, explore new and innovative therapies, and advocate for stronger support systems. With ongoing research and promising breakthroughs on the horizon, there is genuine hope for even better outcomes in the years ahead. By remaining engaged and proactive, we can help create a future in which people living with sickle cell anemia not only manage their condition more effectively but also enjoy greater strength, energy, and overall well-being.

REFERENCES:

1. **Slavov SN, Haddad SK, Silva-Pinto AC, Amarilla AA, Alfonso HL, Aquino VH, Covas DT.** Molecular and phylogenetic analyses of human Parvovirus B19 isolated from Brazilian patients with sickle cell disease and β-thalassemia major and healthy blood donors. Journal of Medical Virology. 2012;84(10):1652-1665.
2. **Obeagu EI, Ochei KC, Nwachukwu BN, Nchuma BO**. Sickle cell anaemia: a review. Scholars Journal of Applied Medical Sciences. 2015;3(6B):224422-52.
3. **Obeagu EI.** Erythropoeitin in Sickle Cell Anaemia: A Review. International Journal of Research Studies in Medical and Health Sciences. 2020;5(2):22-28.
4. **Obeagu EI**. Sickle Cell Anaemia: Haemolysis and Anemia. Int. J. Curr. Res. Chem. Pharm. Sci. 2018;5(10):20-21.
5. **Obeagu EI, Muhimbura E, Kagenderezo BP, Uwakwe OS, Nakyeyune S, Obeagu GU.** An Update on Interferon Gamma and C Reactive Proteins in Sickle Cell Anaemia Crisis. J Biomed Sci. 2022;11(10):84.
6. **Obeagu EI, Bunu UO, Obeagu GU, Habimana JB.** Antioxidants in the management of sickle cell anaemia: an area to be exploited for the wellbeing of the patients. International Research in Medical and Health Sciences. 2023 Sep 11;6(4):12- 17.
7. **Obeagu EI, Ogunnaya FU, Obeagu GU, Ndidi AC**. Sickle cell anaemia: a gestational enigma. European Journal of Biomedical and Pharmaceutical Sciences. 2023;10(9): 72-75
8. **Obeagu EI.** An update on micro RNA in sickle cell disease. Int J Adv Res Biol Sci. 2018;5:157-8.
9. **Obeagu EI, Babar Q. Covid-19 and Sickle Cell Anemia**: Susceptibility and Severity. J. Clinical and Laboratory Research. 2021;3(5):2768-0487.
10. **Obeagu EI, Obeagu GU, Igwe MC, Alum EU, Ugwu OP**. Men's Essential roles in the Management of Sickle Cell Anemia. NEWPORT INTERNATIONAL JOURNAL OF SCIENTIFIC AND EXPERIMENTAL SCIENCES 4(2):20-29.https://doi.org/10.59298/NIJSES/2023/10.3.1111
11. a: **Obeagu EI. Depression in Sickle Cell Anemia** An Overlooked Battle. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(10):41-.
12. **Ifediora AC, Obeagu EI, Akahara IC, Eguzouwa UP.** Prevalence of urinary tract infection in diabetic patients attending Umuahia health care facilities. J Bio Innov. 2016;5(1
13. **Ugwu OP, Alum EU, Okon MB, Aja PM, Obeagu EI, Onyeneke EC.** Ethanol root extract and fractions of Sphenocentrumjollyanum abrogate hyperglycaemia and low body weight in streptozotocin-induced diabetic Wistar albino rats. RPS Pharmacy and Pharmacology Reports. 2023;2(2):rqad010.
14. **Obeagu EI, Obeagu GU.** Utilization of Antioxidants in the management of diabetes mellitus patients. Diabetes, J ClinPrac. 2018;1(102):2.links/5b6c2dec92851ca65053b74e/Utilization-of-Antioxidants-in-the-Management-of-Diabetes-Mellitus.pdf.
15. **Obeagu EI, Okoroiwu IL, Obeagu GU.** Some haematological variables in insulin dependent diabetes mellitus patients in Imo state Nigeria. Int. J. Curr. Res. Chem.

Pharm. Sci. 2016;3(4):110-7. links/5ae4abee458515760ac07a13/Some-haematological-variables-in-insulin-dependent-diabetes-mellitus-patients-in-Imo- state-Nigeria.pdf.

16. **Nwakuilite A, Nwanjo HU, Nwosu DC, Obeagu EI**. Evaluation of some trace elements in streptozocin induced diabetic rats treated with Moringaoleifera leaf powder. WJPMR. 2020;6(12):15-8. links/5fcb587092851
17. **Anyiam AF, Obeagu EI, Obi E, Omosigho PO, Irondi EA, Arinze-Anyiam OC, Asiyah MK.** ABO blood groups and gestational diabetes among pregnant women attending University of Ilorin Teaching Hospital, Kwara State, Nigeria. International Journal of Research and Reports in Hematology. 2022;5(2):113-121.
18. **Okafor CJ, Yusuf SA, Mahmoud SA, Salum SS, Vargas SC, Mathew AE, Obeagu EI, Shaib HK, Iddi HA, Moh'd MS, Abdulrahman WS**. Effect of Gender and Risk Factors in Complications of Type 2 Diabetic Mellitus among Patients Attending Diabetic Clinic in MnaziMmoja Hospital, Zanzibar. Journal of Pharmaceutical Research International. 2021;33(29B):67-78.
19. **Galano ES, Yusuf SA, Ogbonnia SO, Ogundahunsi OA, Obeagu EI, Chukwuani U, Okafor CJ, Obianagha NF.** Effect of Extracts of Kigelia Africana Fruit and Sorghum Bicolor Stalk on the Biochemical Parameters of Alloxan-Induced Diabetic Rats. Journal of Pharmaceutical Research International. 2021;33(25B):86-97.
20. **Kama SC, Obeagu EI, Alo MN, Ochei KC, Ezugwu UM, Odo M, Ikpeme M, Ukeekwe CO, Amaeze AA**. Incidence of Urinary Tract Infection among Diabetic Patients in Abakaliki Metropolis. Journal of Pharmaceutical Research International. 2020 Nov 17;32(28):117-121.
21. **Obeagu EI, Obeagu GU.** Evaluation of Hematological Parameters of Sickle Cell Anemia Patients with Osteomyelitis in A Tertiary Hospital in Enugu, Nigeria. Journal of Clinical and Laboratory Research.2023;6(1):2768-0487.
22. **Obeagu EI, Dahir FS, Francisca U, Vandu C, Obeagu GU**. Hyperthyroidism in sickle cell anaemia. Int. J. Adv. Res. Biol. Sci. 2023;10(3):81-89.
23. **Obeagu EI, Obeagu GU, Akinleye CA, Igwe MC.** Nosocomial infections in sickle cell anemia patients: Prevention through multi-disciplinary approach: A review. Medicine. 2023 Dec 1;102(48):e36462.
24. **Njar VE, Ogunnaya FU, Obeagu EI.** Knowledge And Prevalence of The Sickle Cell Trait Among Undergraduate Students Of The University Of Calabar. Prevalence.;5(100):0-5.
25. **Swem CA, Ukaejiofo EO, Obeagu EI, Eluke B.** Expression of micro RNA 144 in sickle cell disease. Int. J. Curr. Res. Med. Sci. 2018;4(3):26-32.
26. **Obeagu EI, Nimo OM, Bunu UO, Ugwu OP, Alum EU**. Anaemia in children under five years: African perspectives. Int. J. Curr. Res. Biol. Med. 2023;1:1-7.
27. **Obeagu EI. Sickle cell anaemia**: Historical perspective, Pathophysiology and Clinical manifestations. Int. J. Curr. Res. Chem. Pharm. Sci. 2018;5(11):13-15.
28. **Obeagu EI, Obeagu GU**. Sickle Cell Anaemia in Pregnancy: A Review. International Research in Medical and Health Sciences. 2023 Jun 10;6(2):10-13.
29. **Obeagu EI,** Mohamod AH. An update on Iron deficiency anaemia among children with congenital heart disease. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(4):45-48.
30. **Edward U, Osuorji VC, Nnodim J, Obeagu EI.** Evaluationof Trace Elements in Sickle Cell Anaemia Patients Attending Imo State Specialist Hospital, Owerri. Madonna University journal of Medicine and Health Sciences ISSN: 2814-3035. 2022 Mar 4;2(1):218-234.
31. **Umar MI, Aliyu F, Abdullahi MI, Aliyu MN, Isyaku I, Aisha BB, Sadiq RU, Shariff MI, Obeagu EI.** Assessment Of Factors Precipitating Sickle Cell Crises Among Under 5-Years Children Attending Sickle Cell Clinic Of Murtala Muhammad Specialist Hospital, Kano. blood.;11:16.
32. **Obeagu EI.** Vaso-occlusion and adhesion molecules in sickle cells disease. Int J Curr Res Med Sci. 2018;4(11):33-35.
33. **Ifeanyi OE, Stella EI, Favour AA.** Antioxidants In The Management of Sickle Cell Anaemia. Int J Hematol Blood Disord (Internet) 2018 (cited 2021 Mar 4); 3. Available from: https://symbiosisonlinepublishing. com/hematology/hema tology25. php. 2018 Sep.
34. **Nwakulite A, Obeagu EI, Eze R, Vincent CC, Chukwurah EF, Okafor CJ, Ibekwe AM, Adike CN, Chukwuani U, Ifionu BI.** Evaluation of Catalase and Manganese in Type 2 Diabetic Patients in University of Port Harcourt Teaching Hospital. Journal of Pharmaceutical Research International. 2021:40-45.
35. **Nwakulite A, Obeagu EI, Nwanjo HU, Nwosu DC, Nnatuanya IN, Vincent CC, Amaechi CO, Ochiabu O, Barbara MT,**

Ibekwe AM, Okafor CJ. Studies on Pancreatic Gene Expression in Diabetic Rats Treated with Moringaoleifera Leaf. Journal of Pharmaceutical Research International. 2021;33(28A):78-86.

36. **Nwosu DC, Nwanjo HU, Obeagu EI, Ugwu GU, Ofor IB, Okeke A, Ochei KC, Kanu SN, Okpara KE.** Evaluation of Lipoprotein A and Lipid Tetrad Index Pattern in Diabetic Patients Attending Metabolic Clinic in The Federal Medical Centre, Owerri, Imo State.World Journal of Pharmacy and Pharmaceutical Sciences, 2015; 4 (3):126-140
37. **Ezema GO, Omeh NY, Egbachukwu S, Agbo EC, Ikeyi AP, Obeagu EI.** Evaluation of Biochemical Parameters of Patients with Type 2 Diabetes Mellitus Based on Age and Gender in Umuahia. Asian Journal of Dental and Health Sciences. 2023 Jun 15;3(2):32-36. http://ajdhs.com/index.php/journal/article/view/43.
38. **Adu ME, Chukwuani U, Ezeoru V, Okafor CJ, Amaechi CO, Vincent CC, Obeagu GU, Eze R, Nnatuanya IN, Nwosu DC, Nwanjo HU**. Studies on molecular docking of moringaoleifera leaf phytochemical constituents on alpha glucosidase, alpha amylase and dipeptidyl peptidase. Journal of Pharmaceutical Research International. 2021;33(28A):239-345.
39. **Ezugwu UM, Onyenekwe CC, Ukibe NR, Ahaneku JE, Obeagu EI**. Plasma Level of Macromolecules and Mathematical Calculation of Potential Energy in Type 2 Diabetic Individuals at NAUTH, Nnewi, Nigeria. Journal of Pharmaceutical Research International. 2021;33(47B):242-248.
40. **Nwakulite A, Obeagu EI, Eze R, Ugochi VE, Vincent CC, Okafor CJ, Chukwurah EF, Unaeze BC, Amaechi CO, Okwuanaso CB, Chukwuani U.** Estimation of Serum Glutathione Peroxidase in Streptozotocin Induced Diabetic Rat Treated with Bitter Leaf Extract. Journal of Pharmaceutical Research International. 2021;33(30B):200-206.
41. **Okoroiwu IL, Obeagu EI, San Miguel HG, Bote SA, Obeagu GU**. Characterisation of HLA-DR antigen in patients type 1 diabetes mellitus in patient attending a tertairy hospital in Enugu, south-east Nigeria. ACADEMIC JOURNAL. 2023.
42. **Buhari HA, Ahmad AS, Obeagu EI.** Current Advances in the Diagnosis and Treatment of Sickle Cell Anaemia. APPLIED SCIENCES (NIJBAS). 2023;4(1).
43. **Nnodim J, Uche U, Ifeoma U, Chidozie N, Ifeanyi O, Oluchi AA.** Hepcidin and erythropoietin level in sickle cell disease. British Journal of Medicine and Medical Research. 2015;8(3):261-5.
44. **Obeagu EI.** BURDEN OF CHRONIC C ASSOCIATIED FACTORS. Madonna University journal of Medicine and Health Sciences. 2023;3(1):1-6.
45. **Aloh GS, Obeagu EI, Okoroiwu IL, Odo CE, Chibunna OM, Kanu SN, Elemchukwu Q, Okpara KE, Ugwu GU.** Antioxidant-Mediated Heinz Bodies Levels of Sickle Erythrocytes under Drug-Induced Oxidative Stress. European Journal of Biomedical and Pharmaceutical sciences. 2015;2(1):502-507.
46. **Obeagu EI, Malot S, Obeagu GU, Ugwu OP.** HIV resistance in patients with Sickle Cell Anaemia. Newport International Journal of Scientific and Experimental Sciences (NIJSES). 2023;3(2):56-9.
47. **Obeagu EI, Bot YS, Opoku D, Obeagu GU, Hassan AO. Sickle Cell Anaemia:** Current Burden in Africa. International Journal of Innovative and Applied Research. 2023;11(2):12-14.
48. **Obeagu EI, Obeagu GU.** Sickle Cell Anaemia in Pregnancy: A Review. International Research in Medical and Health Sciences. 2023 Jun 10; 6 (2): 10-13.
49. **Obeagu EI, Ogbuabor BN, Ikechukwu OA, Chude CN.** Haematological parameters among sickle cell anemia patients' state and haemoglobin genotype AA individuals at Michael Okpara University of Agriculture, Umudike, Abia State, Nigeria. International Journal of Current Microbiology and Applied Sciences. 2014;3(3):1000-1005.
50. **Ifeanyi OE, Nwakaego OB, Angela IO, Nwakaego CC.** Haematological parameters among sickle cell anaemia... Emmanuel Ifeanyi1, et al. pdf• Obeagu. Int. J. Curr. Microbiol. App. Sci. 2014;3(3):1000-1005.
51. **Obeagu EI, Abdirahman BF, Bunu UO, Obeagu GU.** Obsterics characteristics that effect the newborn outcomes. Int. J. Adv. Res. Biol. Sci. 2023;10(3):134-143.
52. **Obeagu EI, Opoku D, Obeagu GU. Burden of nutritional anaemia in Africa:** A Review. Int. J. Adv. Res. Biol. Sci. 2023;10(2):160-163.
53. **Ifeanyi E. Erythropoietin (Epo) Level in Sickle Cell Anaemia (HbSS)** With Falciparum Malaria Infection in University Health Services, Michael Okpara University of Agriculture, Umudike, Abia State, Nigeria. PARIPEX - INDIAN JOURNAL OF RESEARCH, 2015; 4(6): 258-259
54. **Ifeanyi OE, Nwakaego OB, Angela IO, Nwakaego CC.** Haematological parameters among sickle cell anemias patients in steady

state and haemoglobin genotype AA individuals at Michael Okpara, University of Agriculture, Umudike, Abia State, Nigeria. Int. J. Curr. Microbiol. App. Sci. 2014;3(3):1000-1005.

55. **Ifeanyi OE, Stanley MC, Nwakaego OB.** Comparative analysis of some haematological parameters in sickle cell patients in steady and crisis state at michaelokpara University of agriculture, Umudike, Abia state, Nigeria. Int. J. Curr. Microbiol. App. Sci. 2014;3(3):1046-1050.
56. **Ifeanyi EO, Uzoma GO. Malaria and The Sickle Cell Trait:** Conferring Selective Protective Advantage to Malaria. J Clin Med Res. 2020; 2:1-4.
57. **Odièvre, M.-H., Verger, E., Silva-Pinto, A. C. and Elion, J. J. T. I. j. o. m. r. (2011).** Pathophysiological Insights in Sickle Cell Disease. 134(4): 532.
58. **Okwi, A., Byarugaba, W., Parkes, A., Ocaido, M. J. C. i. M. and Health, C. (2010).** The Reliability of Sickling and Solubility Tests and Peripheral Blood Film Method for Sickle Cell Disease Screening at District Health Centers in Uganda. 7(1):